Are we to believe that all the mishaps with Copaxone pre-launch were accidents and mishandlings by people within Novartis/Sandoz/MNTA that have highly educated/experienced operators to avoid these pitfalls?
Referring in general with management oversight of plant selection - they must have been aware of prior violations, outstanding work to cure violations, new FDA policy of not approving new products - it just does not make sense...it stinks of some hidden motives - quid pro quo where MNTA is the innocent party that gets the short end of the stick. Just a taught
If novartis/sandoz drive these decisions...why would they not announce a plan of action...rather strange in my book
Market Data 
Markets 
AI
